These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 29333255)

  • 1.
    Lau CH; Suh Y
    F1000Res; 2017; 6():2153. PubMed ID: 29333255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Self-Deleting AAV-CRISPR System for
    Li A; Lee CM; Hurley AE; Jarrett KE; De Giorgi M; Lu W; Balderrama KS; Doerfler AM; Deshmukh H; Ray A; Bao G; Lagor WR
    Mol Ther Methods Clin Dev; 2019 Mar; 12():111-122. PubMed ID: 30619914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy.
    Wang Y; Jiang H; Li M; Xu Z; Xu H; Chen Y; Chen K; Zheng W; Lin W; Liu Z; Lin Z; Zhang M
    Gene; 2024 Nov; 927():148733. PubMed ID: 38945310
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Li Q; Su J; Liu Y; Jin X; Zhong X; Mo L; Wang Q; Deng H; Yang Y
    Mol Ther Methods Clin Dev; 2021 Mar; 20():652-659. PubMed ID: 33718515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR Systems Suitable for Single AAV Vector Delivery.
    Stevanovic M; Piotter E; McClements ME; MacLaren RE
    Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
    Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
    Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
    Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
    Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons
    Kumar N; Stanford W; de Solis C; Aradhana ; Abraham ND; Dao TJ; Thaseen S; Sairavi A; Gonzalez CU; Ploski JE
    Front Mol Neurosci; 2018; 11():413. PubMed ID: 30483052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic applications of CRISPR RNA-guided genome editing.
    Koo T; Kim JS
    Brief Funct Genomics; 2017 Jan; 16(1):38-45. PubMed ID: 27562951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine.
    Khoshandam M; Soltaninejad H; Mousazadeh M; Hamidieh AA; Hosseinkhani S
    Genes Dis; 2024 Jan; 11(1):268-282. PubMed ID: 37588217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
    VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
    Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia.
    Zhao H; Li Y; He L; Pu W; Yu W; Li Y; Wu YT; Xu C; Wei Y; Ding Q; Song BL; Huang H; Zhou B
    Circulation; 2020 Jan; 141(1):67-79. PubMed ID: 31779484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications.
    Cheng H; Zhang F; Ding Y
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
    Yu W; Wu Z
    Adv Drug Deliv Rev; 2021 Jan; 168():181-195. PubMed ID: 32603815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
    Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
    Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.
    Taha EA; Lee J; Hotta A
    J Control Release; 2022 Feb; 342():345-361. PubMed ID: 35026352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.